期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

载脂蛋白A5在贝特类药物调脂治疗中的作用机制研究 被引量：2

下载PDF
导出
摘要 目的研究载脂蛋白A5(ApoA5)在贝特类药物调脂中的作用。方法雄性Wistar大鼠随机分4组,取血和肝匀浆检测血脂指标,应用RT-PCR法检测肝脏ApoA5及过氧化物酶体增殖物激活型受体α(PPAR-α)mRNA表达情况,比较ApoA5与各指标间的相关性。结果①血清及肝匀浆甘油三酯(TG):高脂组及非诺贝特低剂量组明显高于正常对照组(P<0.01,P<0.05);非诺贝特高、低剂量组明显低于高脂组(P<0.01);非诺贝特高、低剂量组间有显著差异(P<0.05);②ApoA5和PPAR-α表达:正常对照组明显高于高脂组、非诺贝特低剂量组(P<0.01);高脂组明显低于非诺贝特高、低剂量组(P<0.01);非诺贝特高、低剂量组间有显著差异(P<0.01)。③ApoA5mRNA表达与TG呈明显负相关(P<0.01),与PPAR-α表达呈正相关(P<0.01)。ApoA5与总胆固醇(TC)无明显相关性。结论ApoA5可能是影响血浆TG代谢的重要因素,贝特类药物上调ApoA5和PPAR-α基因表达,与剂量相关。ApoA5在贝特类药物调脂作用可能是通过PPAR-α为作用靶点调控ApoA5发挥降TG作用。
作者 杨轶文 陈焕芹 邱蕾 常静
机构地区 山东大学齐鲁医院干部保健科
出处 《中国老年学杂志》 CAS CSCD 北大核心 2008年第5期420-422,共3页 Chinese Journal of Gerontology
关键词 载脂蛋白A5 过氧化物酶体增殖物激活型受体α 甘油三酯 调脂治疗 贝特类
分类号 R589.2 [医药卫生—内分泌]
  • 相关文献

参考文献10

  • 1Van der Vliet HN, Sammels MG, Leegwater AC,et al. Apolipoprotein AV : a novel apolipoprotein associated with an early phase of liver regeneration[J]. J Biol Chem,2001 ;276(48) :44512-20.
  • 2Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing [J]. Science,2001 ,294(5540) :169-73.
  • 3Everett L, Galli A, Grabb D,et al. The role of hepatic peroxisome proliferator-activated receptors ( PPARs ) in health and disease [ J ]. Liver,2000 ; 20(3) :191-9.
  • 4Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis [ J ]. Biochem Pharmacol,2000 ; 60(8) :1245-50.
  • 5Berger J, Moiler DE. The mechanisms of action of PPARs [ J ]. Annu Rev Med ,2002 ;53 (5) :409-35.
  • 6Prieur X. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element [ J ] . J Biol Chem, 2003 ; 278 ( 28 ) : 25468-80.
  • 7Vu-Dac N, Gervois P, Jakel H ,et al. Apolipoprotein AS, a crucial determinant of plasma triglyceride levels,is highly responsive to peroxisome proliferator-activated receptor alpha activators [ J ]. J Biol Chem, 2003 ; 278 (20) :17982-5.
  • 8Jeppeson J,Hein HO,Suadicani P,et al. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease: an 8-year follow-up in the Copenhagen Male Study [ J ]. Arterioscler Thromb Vasc Biol,1997;17(6) :1114-20.
  • 9O'Brien PJ,Albom WE,Sloan JH,et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons ,and circulates at very low concentrations compared with other apolipoproteins[ J]. Clin Chem,2005 ;51 (2) :351-9.
  • 10刘琼,赵水平.ApoA5单克隆抗体的制备及其临床初步应用[J].医学临床研究,2006,23(2):153-156. 被引量：6

二级参考文献10

  • 1Pennacchio LA,Olivier M,Hubacek JA,et al.An Apolipoprotein influencing TG in humans and mice revealed by comparative sequencing[J].Science,2001,294:169-173.
  • 2Vn der Vliet HN,Schaap FG,Levels JH,et al.Adenoviral overexpression of apolipoprotein AV reduces serum levels of triglycerides and cholesterol in mice[J].Biochem Biophys Res Commun,2002,295:1156-1159.
  • 3Pennacchio LA,Rubin EM.Apolipoprotein A5,a newly identified gene that affects plasma triglyceride levels in humans and mice review[J].Arterioscler Thromb Vasc Biol,2003,23:529-534.
  • 4Beckstead JA,Oda MN,Martin DD,et al.Structure-function studies of human apolipoprotein A-V:a regulator of plasma lipid homostasis[J].Biochemistry,2003,42:9416-9423.
  • 5Weinberg RB,Cook VR,Berkstead JA,et al.Structure and interfacial properties of human apolipoprotein A-V[J].J Biol Chem,2003,278:34438-34444.
  • 6Talmud PJ,Hawe E,Martin S,et al.Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides[J].Hum Mol Genet,2002,11:3039-3046.
  • 7Baroukh N,Bauge E,Akiyama J,et al.Analysis of apolipoprotein A5,C3,and plasma triglyceride concentrations in genetically engineered mice[J].Arterioscler Thromb Vasc Biol,2004,7:1297-1302.
  • 8Van der Vliet HN,Sammels MG,Leegwater AC,et al.Apolipoprotein AV:A novel apolipoprotein associated with an early phase of liver regeneration[J].J Biol Chem,2001,276:44512-44520.
  • 9Ishihara M,Kujiraoka T,Iwasaki T,et al.A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration[J].Journal of Lipid Research,2005,46:2015-2022.
  • 10O'Brien PJ,Alborn WE,Sloan JH,et al.The novel apolipoprotein A5 is present in human serum,is associated with VLDL,HDL,and chylomicrons,and circulates at very low concentrations compared with other apolipoproteins[J].Clin Chem,2005,51:351-359.

共引文献5

同被引文献32

  • 1胡志高,屈晓冰.载脂蛋白M与动脉粥样硬化[J].国外医学（老年医学分册）,2007,28(5):196-199. 被引量：1
  • 2金瑾,周秋丽,胡文祥.黄连解毒汤化学成分分析及其抗高脂血症作用的研究[D].长春:吉林大学,2008.
  • 3Zhang XY,Dong X,Zheng L. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization[J].Acta Histochemica,2003,(01):67-72.doi:10.1078/0065-1281-00687.
  • 4Faber K,Hvidberg V,Moestrup SK. Megalin is a receptor for apolipoprotein M,and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M[J].Molecular Endocrinology,2006,(01):212-218.
  • 5Axler O,Ahnstrǒm J,Dahlbǒck B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma[J].Journal of Lipid Research,2007,(08):1772-1780.doi:10.1194/jlr.M700113-JLR200.
  • 6Wolfrum C,Poy MN,Stoffel M. Apolipoprotein M is required for preβ-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis[J].Nature Medicine,2005,(04):418-442.doi:10.1016/S0140-6736(08)61107-1.
  • 7Christoffersen C,Nielsen LB,Axler O. Isolation and characterization of human apolipoprotein M-containing lipoproteins[J].Journal of Lipid Research,2006,(08):1833-1843.doi:10.1194/jlr.M600055-JLR200.
  • 8Huang XS,Zhao SP,Hu M. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation[J].Medical Hypotheses,2007,(01):136-140.doi:10.1016/S0140-6736(08)61106-X.
  • 9Fiévet C,Staels B.Combination therapy of statins and fibrates in the management of cardiovascular risk[J].Curr Opin Lipidol,2009,20(6):505-511.
  • 10Strauss V,Mellert W,Wiemer J,et al.Increased toxicity when fibrates and statins are administered in combination-A metabolomics approach with rats[J].Toxicol Lett,2012,211(2):187-200.

引证文献2

二级引证文献6

中国老年学杂志
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部